CR20220282A - Agonistas del tlr7 - Google Patents

Agonistas del tlr7

Info

Publication number
CR20220282A
CR20220282A CR20220282A CR20220282A CR20220282A CR 20220282 A CR20220282 A CR 20220282A CR 20220282 A CR20220282 A CR 20220282A CR 20220282 A CR20220282 A CR 20220282A CR 20220282 A CR20220282 A CR 20220282A
Authority
CR
Costa Rica
Prior art keywords
tlr7 agonists
tlr7
agonists
cancer
diseases
Prior art date
Application number
CR20220282A
Other languages
English (en)
Inventor
Stephen E Webber
James Richard Appleman
Original Assignee
Primmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primmune Therapeutics Inc filed Critical Primmune Therapeutics Inc
Publication of CR20220282A publication Critical patent/CR20220282A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agonistas de TLR7 según la fórmula I y su uso en el tratamiento de enfermedades como el cáncer y las enfermedades infecciosas.
CR20220282A 2019-11-26 2020-11-25 Agonistas del tlr7 CR20220282A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940622P 2019-11-26 2019-11-26
PCT/US2020/062344 WO2021108649A1 (en) 2019-11-26 2020-11-25 Tlr7 agonists

Publications (1)

Publication Number Publication Date
CR20220282A true CR20220282A (es) 2022-11-28

Family

ID=75974715

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220282A CR20220282A (es) 2019-11-26 2020-11-25 Agonistas del tlr7

Country Status (18)

Country Link
US (3) US11692005B2 (es)
EP (1) EP4065155A4 (es)
JP (1) JP7777870B2 (es)
KR (1) KR20220150879A (es)
CN (1) CN115427063A (es)
AU (1) AU2020391487B2 (es)
BR (1) BR112022010165A2 (es)
CA (1) CA3163093A1 (es)
CL (1) CL2022001377A1 (es)
CO (1) CO2022008835A2 (es)
CR (1) CR20220282A (es)
EC (1) ECSP22049906A (es)
IL (1) IL293293A (es)
MX (1) MX2022006307A (es)
PE (1) PE20221324A1 (es)
PH (1) PH12022551280A1 (es)
TW (1) TWI867097B (es)
WO (1) WO2021108649A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5136030A (en) 1988-05-05 1992-08-04 Scripps Clinic And Research Foundation Immunostimulating guanine derivatives, compositions and methods
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
WO1994011003A1 (en) 1992-11-13 1994-05-26 The Scripps Research Institute Cancerous b cell treatment using substituted nucleoside derivatives
US5441942A (en) * 1994-05-27 1995-08-15 The Scripps Research Institute 2'3'-dideoxy-2',3'-didehydro-7,8-disubstituted guanosines and their immunostimulative effect
ATE271063T1 (de) 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
TR200601784T2 (tr) 1999-11-12 2007-01-22 Pharmasset Ltd. 2'-deoksi-L-nükleositlerin sentezi
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
EP1667694B1 (en) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
CN102504001B (zh) * 2004-12-17 2015-02-25 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
MX2010001785A (es) 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
WO2010014913A1 (en) * 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
US20120095077A1 (en) 2009-03-23 2012-04-19 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
IN2014CN04251A (es) 2011-11-09 2015-07-17 Ascend Biopharmaceuticals Ltd
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CA2963717C (en) 2014-12-08 2023-10-10 F. Hoffmann-La Roche Ag 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
CN107427514B (zh) * 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
SMT202100225T1 (it) * 2016-12-20 2021-05-07 Astrazeneca Ab Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro
CN112533607B (zh) * 2018-05-25 2025-01-07 普利缪尼治疗学股份有限公司 Tlr7激动剂

Also Published As

Publication number Publication date
AU2020391487A1 (en) 2022-07-07
TW202134240A (zh) 2021-09-16
US20260055132A1 (en) 2026-02-26
US20210155652A1 (en) 2021-05-27
EP4065155A1 (en) 2022-10-05
PE20221324A1 (es) 2022-09-09
WO2021108649A1 (en) 2021-06-03
US20240116974A1 (en) 2024-04-11
BR112022010165A2 (pt) 2022-08-09
AU2020391487B2 (en) 2026-04-23
JP7777870B2 (ja) 2025-12-01
CN115427063A (zh) 2022-12-02
US11692005B2 (en) 2023-07-04
CO2022008835A2 (es) 2022-07-19
IL293293A (en) 2022-07-01
PH12022551280A1 (en) 2024-01-08
ECSP22049906A (es) 2022-07-29
MX2022006307A (es) 2022-08-22
CA3163093A1 (en) 2021-06-03
TWI867097B (zh) 2024-12-21
EP4065155A4 (en) 2023-11-29
JP2023503996A (ja) 2023-02-01
CL2022001377A1 (es) 2023-04-10
US12187759B2 (en) 2025-01-07
KR20220150879A (ko) 2022-11-11

Similar Documents

Publication Publication Date Title
MY209609A (en) Immunomodulators, compositions and methods thereof
NZ784224A (en) Parp1 inhibitors
WO2018190719A3 (en) Anti-sirp alpha antibodies
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
JOP20200315B1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2019001920A (es) Arn la terapia contra el cancer.
PH12020551994A1 (en) Tlr7 agonists
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2019012676A (es) Derivados de 2-aminoquinolina.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2022007522A (es) Anticuerpos anti-cd27.
MX2015010125A (es) Derivados de piridazinona-amidas.
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2019004375A (es) Inhibidores de bromodominios.
PH12022551280A1 (en) Tlr7 agonists
WO2019209232A3 (en) The use of terpenic coumarine derivative molecules in the treatment of cancer disease
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
MX2022008391A (es) Anticuerpos epiteliales específicos de cadherina.